HighTide Therapeutics, Inc. (HTTIF)

Market Cap	213.00M +189.7%
Revenue (ttm)	n/a
Net Income	-35.02M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	9,600
Open	0.4206
Previous Close	0.4206
Day's Range	0.4206 - 0.4206
52-Week Range	0.3358 - 0.4883
Beta	n/a
RSI	n/a
Earnings Date	Mar 27, 2026

About HighTide Therapeutics

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis (MASH); in phase II clinical trial to treat severe hypertriglyceridemia; and in phase II clinical trial to treat primary sclerosing cholangitis, as well as i...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 57
• Stock Exchange: OTCMKTS
• Ticker Symbol: HTTIF

Financial Performance

Financial numbers in CNY